Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 1/20 | 0.35 |
| ▸ | CTSK | P43235 | 3/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | APLNR | P35414 | 1/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.33 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.33 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.33 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.33 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.33 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.33 |
| ▸ | RELA | Q04206 | 1/20 | 0.33 |
| ▸ | BTK | Q06187 | 1/20 | 0.32 |
| ▸ | CTSL | P07711 | 1/20 | 0.32 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20338584 | 1.00 | P2RX7 (0.35) | P2RX7CTSKGAAMEN1MAPK1 | |
| SCHEMBL20338609 | 1.00 | P2RX7 (0.35) | P2RX7CTSKGAAMEN1MAPK1 | |
| SCHEMBL2500185 | 0.98 | CTSK (0.35) | P2RX7CTSKGAAMEN1MAPK1 | |
| SCHEMBL571145 | 0.95 | CTSK (0.35) | P2RX7CTSKGAAMEN1MAPK1 | |
| SCHEMBL570580 | 0.92 | CTSK (0.36) | CTSKGAAMEN1MAPK1KMT2A | |
| SCHEMBL28607231 | 0.83 | CTSK (0.35) | CTSKGAAMEN1MAPK1KMT2A | |
| SCHEMBL29280568 | 0.81 | GAA (0.37) | CTSKGAAMEN1MAPK1KMT2A | |
| SCHEMBL25645220 | 0.79 | APLNR (0.36) | CTSKGAAMEN1MAPK1KMT2A | |
| SCHEMBL1162997 | 0.79 | BTK (0.36) | P2RX7CTSKGAAMEN1MAPK1 | |
| SCHEMBL28367798 | 0.77 | BTK (0.35) | P2RX7CTSKGAAMEN1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114478627-A | Allylation monophosphine ligand and preparation method thereof | 湖北大学 | 2022-05-13 | — | — | CN | claimed |
| CN-114478627-A | Allylation monophosphine ligand and preparation method thereof | 湖北大学 | 2022-05-13 | — | — | CN | disclosed |
| US-20180215780-A1 | C-3 NOVEL TRITERPENONE WITH C-28 REVERSE AMIDE DERIVATIVES AS HIV INHIBITORS | DFH THERAPEUTICS, INC. | 2018-08-02 | — | — | US | disclosed |
| US-20180186860-A1 | SYNTHETIC APOLIPOPROTEINS, AND RELATED COMPOSITIONS METHODS AND SYSTEMS FOR NANOLIPOPROTEIN PARTICLES FORMATION | U.S. DEPARTMENT OF ENERGY | 2018-07-05 | — | — | US | disclosed |
| US-20170008921-A1 | C-3 NOVEL TRITERPENONE WITH C-28 REVERSE AMIDE DERIVATIVES AS HIV INHIBITORS | HETERO RESEARCH FOUNDATION (IN) | 2017-01-12 | — | — | US | disclosed |
| US-8030499-B2 | 1,3-dihydro-2H-indole-2-one compound and pyrrolidine-2-one compound fused with aromatic heterocycle | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-10-04 | — | — | US | disclosed |
| WO-2009132452-A1 | DIARYL-CYCLYLALKYL DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS LTD. (CA) | 2009-11-05 | — | — | WO | disclosed |
| US-20090270338-A1 | DIARYL-CYCLYLALKYL DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2009-10-29 | — | — | US | disclosed |
| US-20080318923-A1 | 1,3-Dihydro-2H-Indole-2-One Compound and Pyrrolidine-2-One Compound Fused With Aromatic Heterocycle | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2008-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270338-A1 | DIARYL-CYCLYLALKYL DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | CACNA1G, CACNA1H, CACNA1B | P2RX7 378/4885CTSK 647/4885GAA 2152/4885 |
| US-20170008921-A1 | C-3 NOVEL TRITERPENONE WITH C-28 REVERSE AMIDE DERIVATIVES AS HIV INHIBITORS | ERG28, CCR3, ACBD3 | P2RX7 3187/4885CTSK 1531/4885GAA 3309/4885 |
| US-20180215780-A1 | C-3 NOVEL TRITERPENONE WITH C-28 REVERSE AMIDE DERIVATIVES AS HIV INHIBITORS | ERG28, CCR3, ACBD3 | P2RX7 3223/4885CTSK 1385/4885GAA 2905/4885 |
| US-20080318923-A1 | 1,3-Dihydro-2H-Indole-2-One Compound and Pyrrolidine-2-One Compound Fused With Aromatic Heterocycle | AVPR1B, AVPR1A, AVPR2 | P2RX7 4175/4885CTSK 1512/4885GAA 3124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.